DENVER / Dec 28, 2023 / Business Wire / Modivcare Inc., (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced that Heath Sampson, Modivcare’s President and Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 11, 2024 at 8:15 a.m. (PST). Management will also host investor meetings while attending the conference.
A link to the live webcast of the Company’s presentation can be found on Modivcare’s Investor Relations website at Modivcare Inc. - Investor Overview. A replay of each presentation will be available for 30 days following the date of the presentation.
About Modivcare
Modivcare Inc. (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their members. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal care and remote patient monitoring. To learn more about Modivcare, please visit www.modivcare.com.
| Last Trade: | US$11.13 |
| Daily Change: | 0.24 2.20 |
| Daily Volume: | 412,581 |
| Market Cap: | US$158.940M |
October 23, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
